In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
BNN
AION Labs, collaborating with industry leaders, invites innovators to join their mission in leveraging AI and ML to target RNA for small molecule therapeutics. This initiative could redefine drug discovery and benefit global health.
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
PR Newswire
Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “AI/ML Platform for Targeting RNA with Small Molecules”
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
PharmiWeb
Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “AI/ML Platform for Targeting RNA with Small Molecules“
Japan-Germany Collaboration for Cancer Research to Design Novel Immunotherapies
BioSpectrum
BioMed X Institute and Ono Pharmaceutical launch new collaboration in cancer research.
BioMed X and Ono Pharmaceutical Enter Joint Cancer Research Project
PharmaTimes
In 2020, there were over ten million deaths worldwide associated with cancer. The BioMed X Institute and Ono Pharmaceutical have announced a new joint research collaboration for cancer research.
BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
BioSpace
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
Yahoo! Finance
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
DenovAI Biotech Creates Designer Antibodies for Any Disease
AzoRobotics
A start-up named DenovAI, founded by a former EMBL staff scientist, is pioneering a revolutionary approach to expedite and reduce costs in antibody discovery.
Using artificial intelligence to discover therapeutic antibodies
EurekAlert!
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.
Using artificial intelligence to discover therapeutic antibodies
European Molecular Biology Laboratory (EMBL)
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.
BioMed X Launches a New Call for Application in Autoimmune Disease Research
Yahoo! Finance
BioMed X, a biomedical research institute, announced the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.
BioMed X Launches a New Call for Application in Autoimmune Disease Research
PharmiWeb
A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.
BioMed X Launches a New Call for Application in Autoimmune Disease Research
MarketWatch
BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.
BioMed X Launches a New Call for Application in Autoimmune Disease Research
BioSpace
A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.
BioMed X and AbbVie Start New Research Project in the USA
Newswire
BioMed X inaugurates its new institute in the USA with a research project on complex ex vivo models of tissue inflammation in collaboration with AbbVie.
BioMed X and AbbVie Start New Research Project in the USA
Yahoo! Finance
BioMed X, an independent biomedical research institute, announces the start of a research project in collaboration with AbbVie to be hosted by the new BioMed X Institute in New Haven, CT, USA. The project aims to generate an organotypic human arterial model with sufficient complexity to recapitulate key characteristics of chronic autoimmune disease onset, progression, and resolution, with the long-term…
The BioMed X Institute: BioMed X and AbbVie Start New Research Project in the USA
FinanzNachrichten
BioMed X, an independent biomedical research institute, announces the start of a research project in collaboration with AbbVie to be hosted by the new BioMed X Institute in New Haven, CT, USA.
BioMed X and AbbVie Start New Research Project in the USA
Bloomberg
BioMed X inaugurates its new institute in the USA with a research project on complex ex vivo models of tissue inflammation in collaboration with AbbVie.
BioMed X and Sanofi begin joint research on AI-driven drug development
Pharmaceutical Technology
This latest effort is yet another AI play from BioMed X, hoping to capitalise on a rapidly growing market.
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
Yahoo! Finance
BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE). The end goal of this research project is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations…
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
Newswire
The “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE) team joins eight other active research teams at the BioMed X Institute in Germany, and it is one of four new projects launched by BioMed X in 2023. To learn more about this new AI-based research group, visit the BioMed X Institute website at www.bio.mx.